# Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

> **NCT00055562** · PHASE2,PHASE3 · COMPLETED · sponsor: **Celgene Corporation** · enrollment: 274 (—)

## Conditions studied

- Melanoma
- Neoplasm Metastasis

## Interventions

- **DRUG:** CC 5013

## Key facts

- **NCT ID:** NCT00055562
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** —
- **Final completion:** 2004-12
- **Target enrollment:** 274 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00055562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00055562, "Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00055562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*